Buprenorphine depot - BioDelivery Sciences International/Evonik

Drug Profile

Buprenorphine depot - BioDelivery Sciences International/Evonik

Alternative Names: Buprenorphine long acting - BioDelivery Sciences International/Evonik; Buprenorphine microparticle depot - BioDelivery Sciences International/Evonik; Sustained release buprenorphine injection - BioDelivery Sciences International

Latest Information Update: 26 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Evonik
  • Developer BioDelivery Sciences International; Evonik
  • Class Cyclopropanes; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Opioid abuse; Pain

Most Recent Events

  • 15 May 2017 US FDA approves IND application for Buprenorphine depot before May 2017
  • 21 Mar 2017 9213197- added Sustained Release Buprenorphine Injection as a synonym, added FE
  • 17 Mar 2017 BioDelivery Sciences International plans a phase I trial for Opioid abuse
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top